» Articles » PMID: 35409089

Wwox Binding to the Murine Brca1-BRCT Domain Regulates Timing of Brip1 and CtIP Phospho-Protein Interactions with This Domain at DNA Double-Strand Breaks, and Repair Pathway Choice

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Apr 12
PMID 35409089
Authors
Affiliations
Soon will be listed here.
Abstract

Wwox-deficient human cells show elevated homologous recombination, leading to resistance to killing by double-strand break-inducing agents. Human Wwox binds to the Brca1 981-PPLF-984 Wwox-binding motif, likely blocking the pChk2 phosphorylation site at Brca1-S988. This phosphorylation site is conserved across mammalian species; the PPLF motif is conserved in primates but not in rodents. We now show that murine Wwox does not bind Brca1 near the conserved mouse Brca1 phospho-S971 site, leaving it open for Chk2 phosphorylation and Brca1 activation. Instead, murine Wwox binds to Brca1 through its BRCT domain, where pAbraxas, pBrip1, and pCtIP, of the A, B, and C binding complexes, interact to regulate double-strand break repair pathway response. In Wwox-deficient mouse cells, the Brca1-BRCT domain is thus accessible for immediate binding of these phospho-proteins. We confirm elevated homologous recombination in Wwox-silenced murine cells, as in human cells. Wwox-deficient murine cells showed increased ionizing radiation-induced Abraxas, Brca1, and CtIP foci and long resected single-strand DNA, early after ionizing radiation. Wwox deletion increased the basal level of Brca1-CtIP interaction and the expression level of the MRN-CtIP protein complex, key players in end-resection, and facilitated Brca1 release from foci. Inhibition of phospho-Chk2 phosphorylation of Brca1-S971 delays the end-resection; the delay of premature end-resection by combining Chk2 inhibition with ionizing radiation or carboplatin treatment restored ionizing radiation and platinum sensitivity in Wwox-deficient murine cells, as in human cells, supporting the use of murine in vitro and in vivo models in preclinical cancer treatment research.

Citing Articles

Zfra Overrides WWOX in Suppressing the Progression of Neurodegeneration.

Chen Y, Liu T, Wen K, Hsu C, Sze C, Chang N Int J Mol Sci. 2024; 25(6).

PMID: 38542478 PMC: 10970703. DOI: 10.3390/ijms25063507.


Unveiling the relationship between WWOX and BRCA1 in mammary tumorigenicity and in DNA repair pathway selection.

Bidany-Mizrahi T, Shweiki A, Maroun K, Abu-Tair L, Mali B, Aqeilan R Cell Death Discov. 2024; 10(1):145.

PMID: 38499540 PMC: 10948869. DOI: 10.1038/s41420-024-01878-8.

References
1.
Wang B, Matsuoka S, Ballif B, Zhang D, Smogorzewska A, Gygi S . Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science. 2007; 316(5828):1194-8. PMC: 3573690. DOI: 10.1126/science.1139476. View

2.
Anand R, Ranjha L, Cannavo E, Cejka P . Phosphorylated CtIP Functions as a Co-factor of the MRE11-RAD50-NBS1 Endonuclease in DNA End Resection. Mol Cell. 2016; 64(5):940-950. DOI: 10.1016/j.molcel.2016.10.017. View

3.
Glover J . Insights into the molecular basis of human hereditary breast cancer from studies of the BRCA1 BRCT domain. Fam Cancer. 2006; 5(1):89-93. DOI: 10.1007/s10689-005-2579-z. View

4.
Ramos D, Abba M, Lopez-Guerrero J, Rubio J, Solsona E, Almenar S . Low levels of WWOX protein immunoexpression correlate with tumour grade and a less favourable outcome in patients with urinary bladder tumours. Histopathology. 2008; 52(7):831-9. PMC: 4151645. DOI: 10.1111/j.1365-2559.2008.03033.x. View

5.
Yu X, Wu L, Bowcock A, Aronheim A, Baer R . The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J Biol Chem. 1998; 273(39):25388-92. DOI: 10.1074/jbc.273.39.25388. View